Cancer Cancer
Conditions
Interventions
Current interventions as of 14/12/2016:
Stage 1
Patients with pain from advanced cancer will be interviewed to find out how they use their community pharmacy. They wil
Sponsors
University of Bradford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Stage 1: 1. Aged 16 or over 2. Have advanced cancer and pain 3. Been receiving strong opiods for 2 weeks or more (morphine, fentanyl, buprenorphine, diamorphine, hydromorphone, methadone or oxycodone) 4. Have a good level of spoken and written English (we do not have the resources to employ an interpreter at this time) 5. Have the capacity to provide informed consent to participate 6. Be deemed well enough to take part by their healthcare provider Stage 3 - as well as the criteria for stage 1 the participants should: 1. Regularly use the pharmacies participating in the study it is not feasible to train all the local pharmacists to provide this service at this point but may be an option for future role out. Patients with advanced cancer will be defined as: Those with metastatic cancer (histological, cytological or radiological evidence) AND/OR those receiving anti-cancer therapy with palliative intent Patients with pain will be defined as: Those receiving strong opiod analgesic treatment for cancer symptom-related pain AND/OR those receiving analgesics for treatment of cancer therapy-related pain
Exclusion criteria
Exclusion criteria: Stage 1 and 3: 1. Are unconscious or confused 2. Are, in the opinion of the clinician, unable to understand and complete the interview or questionnaires (due to cognitive impairment for example) 3. Are unwilling to provide informed consent 4. We are not looking to recruit patients in the last days of life so we will exclude those who have received anticipatory medicines in readiness for this Stage 3 only: 1. They do not use one of the participating pharmacies (although these patients may be included at a later date if the study is expanded) 2. Patients who are deemed ethically inappropriate to approach for example where death is imminent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measures as of 14/12/2016: The acceptability of the pain medicines consultation to patients, assessed by postal questionnaire two weeks after their final consultation Previous primary outcome measures: Feasibility of the process; Timepoint(s): by the end of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Added 14/12/2016: The feasibility of delivering the pain medicines consultation to patients with advanced cancer, assessed by how many patients are recruited and whether the consultations can be delivered to them | — |
Countries
England, United Kingdom
Outcome results
None listed